National Emerging Infectious Diseases Laboratories Operations

整体 摘要 波士顿大学（BU）的国家生物遏制实验室（NBL）被称为国家新兴实验室。 传染病实验室（NEIDL）。它由BU拥有和运营，位于波士顿 大学医学院（BUMC）毗邻BU医学院，研究生科学课程， 波士顿大学公共卫生学院和附属教学医院波士顿医学中心。NEIDL的 使命是：（1）对新兴传染病进行创新的基础，转化和临床研究 （2）研究和开发诊断测试、治疗方法和疫苗，以促进公众健康; 在这些研究领域提供培训，并在发生生物防御时支持国家应对措施 建立一个最重视社区和实验室的研究设施 安全和安保。为了成功地完成这些任务，NEIDL的目标是：（1）招募和 培养一支具有所需科学学科专门知识的调查人员和研究人员队伍， 调查由A、B和C类病原体引起的新发传染病的发病机制，包括 在大学内，在美国和国际上的合作;（2）开发动物模型， 对这些病原体进行比较研究，尽可能接近地模仿人类疾病过程，并建立 建立和使用相关动物模型和创新兽医研究支持的能力;（3） 在动物和人类中进行转化，临床前和临床研究;（4）开发方法学 需要推进这些病原体的疫苗、治疗剂和诊断剂的开发和测试;（5） 培训下一代研究科学家和相关支持人员的要求，以执行 在安全可靠的环境中进行最大限度的遏制研究;（6）保持必要的灵活性， 在生物防御紧急情况下支持国家反应;（7）建立“安全第一”的环境 在研究所开展的所有活动。自2004年开放BSL-4和ABSL-4级别的研究以来， 2018年，NEIDL已迅速向前迈进，招聘更多的教师，他们的技能和兴趣都扩大， 补充现有的专业知识，带来创新的新见解和方法，以扩大我们的科学 能力，开辟新病原体的研究。为了推进疫苗和治疗，NEIDL 已扩大其监管合规小组和做法，以允许在良好的条件下进行研究， 记录的做法。NEIDL专注于并支持由我们教师领导的创新科学 因此，我们也继续发展我们的综合研究支持服务， 需要支持BSL-4研究，以更好地反映和提供新技术和研究的机会 方法，以保持在科学的前沿。

Overall Abstract The National Biocontainment Laboratory (NBL) at Boston University (BU) is known as the National Emerging Infectious Diseases Laboratories (NEIDL). It is owned and operated by BU and is located on the Boston University Medical Campus (BUMC) adjacent to the BU School of Medicine, the Graduate Sciences program, the BU School of Public Health, and the affiliated teaching hospital, Boston Medical Center. The NEIDL's missions are: (1) To perform innovative basic, translational and clinical research on emerging infectious diseases in order to develop diagnostic tests, treatments and vaccines to promote the public's health; (2) To provide training in these areas of research and to support a national response in the event of a biodefense emergency; and (3) To establish a research facility with the highest attention to community and laboratory safety and security. In order to successfully achieve these missions, the NEIDL's goals are to: (1) Recruit and develop a cadre of investigators and research staff with expertise in the scientific disciplines required to investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents, including collaborations within the university, in the United States, and internationally; (2) Develop animal models for the comparative study of these pathogens, mimicking as closely as possible the human disease process, and build capacity for the creation and use of relevant animal models and innovative veterinary research support; (3) Perform translational, preclinical and clinical research in animals and humans; (4) Develop the methodologies needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents; (5) Train the next generation of research scientists and related support personnel in the requirements to perform maximum containment research in a safe and secure environment;( 6) Maintain the flexibility needed to support a national response in the event of a biodefense emergency; (7) Establish a "safety first" environment for the conduct of all activities in the Institute. Since opening for research at the BSL-4 and ABSL-4 levels in 2018, NEIDL has rapidly moved forward to recruit additional faculty whose skills and interests both expand and complement existing expertise, bring innovative new insights and methodology to expand our scientific capabilities, open up research on new pathogens. In order to advance vaccines and therapeutics, the NEIDL has expanded its Regulatory Compliance Group and practices to permit studies to be carried out under Well- Documented practices. The NEIDL focuses on and supports innovative science, led by our faculty investigators, and as a result we also continue to evolve our integrated research support services to provide support needed for BSL-4 research to better reflect and provide access to new technology and research approaches, in order to remain at the leading edge of science.